EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)

被引：0
|
作者：
Davis, I. D. [1 ]
Long, A. [2 ,13 ]
Martin, A. [2 ,13 ]
Espinoza, D. [2 ,13 ]
Yip, S. [2 ,13 ]
Thompson, J. F. [2 ]
Kichenadasse, G. [3 ]
Harrison, M. [4 ]
Lowenthal, R. M. [6 ]
Pavlakis, N. [5 ]
Azad, A. [7 ]
Kannourakis, G. [8 ]
Steer, C. [9 ]
Goldstein, D. [10 ]
Shapiro, J. [11 ]
Stockler, M. R. [2 ,4 ,12 ,13 ]
机构：
[1] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[5] Univ Sydney, Royal N Shore Hosp, Sydney, NSW 2006, Australia
[6] Royal Hobart Hosp, Hobart, Tas, Australia
[7] Austin Hlth, Melbourne, Vic, Australia
[8] Ballarat Oncol & Haematol Serv, Ballarat, Vic, Australia
[9] Border Med Oncol, Wodonga, Vic, Australia
[10] Univ New S Wales, Prince Wales Hosp, Sydney, NSW, Australia
[11] Cabrini Inst, Melbourne, Vic, Australia
[12] Concord Canc Ctr, Concord, NSW, Australia
[13] Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/j.ejca.2014.03.255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P0211
引用
收藏
页码：E68 / E69
页数：2
相关论文
共 50 条
  • [31] Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Feldman, Darren R.
    Ged, Yasser
    Lee, Chung-Han
    Knezevic, Andrea
    Molina, Ana M.
    Chen, Ying-Bei
    Chaim, Joshua
    Coskey, Devyn T.
    Murray, Samuel
    Tickoo, Satish K.
    Reuter, Victor E.
    Patil, Sujata
    Xiao, Han
    Aghalar, Jahan
    Apollo, Arlyn J.
    Carlo, Maria I.
    Motzer, Robert J.
    Voss, Martin H.
    CANCER, 2020, 126 (24) : 5247 - 5255
  • [32] Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    Barrios, Carlos H.
    Hernandez-Barajas, David
    Brown, Michael P.
    Lee, Se-Hoon
    Fein, Luis
    Liu, Jin-Hwang
    Hariharan, Subramanian
    Martell, Bridget A.
    Yuan, Jinyu
    Bello, Akintunde
    Wang, Zhixiao
    Mundayat, Rajiv
    Rha, Sun-Young
    CANCER, 2012, 118 (05) : 1252 - 1259
  • [33] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Re: Quality-Adjusted Survival with First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)
    Laguna, Pilar M.
    JOURNAL OF UROLOGY, 2021, 205 (06): : 1819 - 1820
  • [35] Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
    Escudier, Bernard
    Molinie, Vincent
    Bracarda, Sergio
    Maroto, Pablo
    Szczylik, Cezary
    Nathan, Paul
    Negrier, Sylvie
    Weiss, Claudia
    Porta, Camillo
    Gruenwald, Viktor
    Albiges, Laurence
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : 226 - 235
  • [36] First-line chemotherapy trial in advanced endometrial carcinoma
    Siqing Fu
    John J. Kavanagh
    Current Oncology Reports, 2004, 6 (6) : 483 - 483
  • [37] Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    Motzer, R. J.
    Hutson, T. E.
    Olsen, M. R.
    Hudes, G. R.
    Burke, J. M.
    Edenfield, W. J.
    Wilding, G.
    Martell, B.
    Hariharan, S.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [38] First-Line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial
    Levy, Sonja
    Verbeek, Wieke H. M.
    Eskens, Ferry A. L. M.
    van den Berg, Jose G.
    de Groot, Derk Jan A.
    van Leerdam, Monique E.
    Tesselaar, Margot E. T.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [39] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Fowles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma
    Clark, PE
    Hall, MC
    Miller, A
    Ridenhour, KP
    Stindt, D
    Lovato, JF
    Patton, SE
    Brinkley, W
    Das, S
    Torti, FM
    UROLOGY, 2004, 63 (06) : 1061 - 1065
12345